Updated:
SOLENO THERAPEUTICS INC
At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS)...
SOLENO THERAPEUTICS INC
At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
Corporate office
United States
Sector focus
Frequently asked questions
Who makes investment and strategic decisions at Soleno Therapeutics?
Soleno Therapeutics is led by a publicly traded board of directors and executive management team. Anish Bhatnagar, MD, serves as CEO (per company filings). Key operational decisions are made by the executive team, subject to board approval, with the board representing shareholder interests.
How is Soleno Therapeutics structured? Is it a family office?
No. Soleno Therapeutics is a publicly traded clinical-stage biopharmaceutical company (NASDAQ: SLNO), not a family office. It operates as a C-corporation with shareholders and an elected board, distinct from the private capital management structure of a family office.
What drug candidate is Soleno currently developing?
Soleno's lead asset is DCCR (diazoxide choline), a once-daily oral tablet for Prader-Willi syndrome (PWS), a rare genetic disorder. DCCR is intended to treat hyperphagia (extreme hunger) and other symptoms of PWS (per company Phase 3 data, 2024). The company has completed pivotal trials and is preparing for FDA submission.
Does Soleno Therapeutics invest in other companies or funds?
No public disclosures indicate that Soleno makes external investments in other companies or funds. Its capital is allocated solely to internal R&D and clinical development of DCCR. The firm is a drug developer, not an investment vehicle.
Where does the underlying wealth for Soleno come from?
Soleno Therapeutics is publicly traded, so its capital comes from equity and debt markets, not from a single family fortune. Major institutional investors include entities like BlackRock and Vanguard (per SEC filings, 2024), but the company has no disclosed single-family or multi-family office backing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: